课题基金 / 基金详情

A Systems Biology Approach for Pediatric and Adult Autoimmune Diseases

A Systems Biology Approach for Pediatric and Adult Autoimmune Diseases
儿童和成人自身免疫性疾病的系统生物学方法
批准号:
8470118
负责人:
Maria Virginia Pascual
金额:
$62.99万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-05-15 至 2014-04-30
关键词:
Academic Medical CentersAddressAdolescentAdultAdult DermatomyositisAntigensAppointmentAreaAutoantigensAutoimmune DiseasesAutoimmune ProcessAutoimmunityAutomobile DrivingB-LymphocytesBasic ScienceBiologicalBiological AssayBiological MarkersBiologyBlindedBloodBlood typing procedureCD4 Positive T LymphocytesCaringCell MaturationCellsCellular biologyChildChildhoodChronic small plaque psoriasisClinicalClinical InvestigatorClinical ResearchClinical SciencesClinical TrialsClinical Trials DesignCollaborationsCommitCommunicable DiseasesComplexControlled Clinical TrialsDataDatabasesDendritic Cell VaccineDendritic CellsDermatologyDermatomyositisDevelopmentDiabetes MellitusDiagnostic testsDisciplineDiseaseDouble-Blind MethodEarly treatmentEnvironmentGene Expression ProfilingGenesGenomicsGoalsHarvestHelper-Inducer T-LymphocyteHospitalsHumanImmune responseImmunologistImmunologyIn VitroIndividualInstitutesInterferonsInterleukin-1Interleukin-12Interleukin-17Islets of LangerhansIslets of Langerhans TransplantationLaboratoriesLaboratory ResearchLearningLupusMalignant NeoplasmsMeasuresMedical centerMethodsMultiple SclerosisPathogenesisPathway interactionsPatientsPediatric NeurologyPhasePhysiciansPilot ProjectsPlacebosProcessPropertyProtocols documentationPsoriasisPsoriatic ArthritisRandomizedResearchResearch InfrastructureResearch PersonnelResourcesRheumatologyRoleSafetySamplingSampling StudiesScientistSystemSystemic Lupus ErythematosusSystems BiologyT cell responseT-LymphocyteT-Lymphocyte SubsetsTechniquesTestingTexasTimeTransplantationTumor ImmunityUniversitiesVaccinesanakinraanalytical toolassay developmentbasebench to bedsidebiological systemscongenital immunodeficiencycytokinedesignexperienceflexibilityimprovedinnovationinterestmelanomamultidisciplinarynew therapeutic targetnovelnovel diagnosticsoverexpressionprogramsresponsetype I and type II diabetes

项目摘要

项目成果

Maria Virginia Pascual的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):我们建议创建一个自身免疫卓越中心,该中心将整合临床医生,人类免疫学家(基础和翻译),具有自身免疫临床专业知识和研究经验的医生科学家,生物信息学家和老年组学/系统生物学家的努力。总的来说,这个团队在临床试验方面拥有广泛的背景,并在融合基础和临床科学方面有着良好的记录。该团队致力于将创新的治疗方法从实验室工作台带到患者的床边。在这种协作环境中,系统生物学方法被提出来关注儿童和成人自身免疫性疾病。 该中心的目标是: 1)评估新型靶向治疗的疗效,2)使用最先进的基因组方法开发简单而稳健的生物标志物,3)了解最近发现的T细胞亚群在疾病发病机制中的作用,以及4)评估儿科和成人自身免疫性疾病中的抗原特异性反应。 这些项目将提供一个更好地了解特定的自身免疫性疾病的发病机制,并使我们能够开发一种策略,以评估疾病的活动的基础上,新的转录标记,以及确定自身抗原特异性免疫反应。 该中心将提供: 1)针对银屑病和皮肌炎特定细胞因子的创新临床试验。 2)皮肌炎、牛皮癣、狼疮和多发性硬化症生物标志物的发展。 3)皮肌炎治疗新靶点的鉴定。 4)开发检测自身抗原特异性免疫应答的试验。 5)人类自身免疫性疾病微阵列数据库的建立。 临床部分(Cush,J) 临床组件描述(由申请人提供):贝勒免疫学研究所旨在汇集一支杰出的临床研究团队,对特定的自身免疫性疾病进行尖端的临床试验。这一独特的研究人员和临床医生小组在贝勒大学医学中心、UT西南医学中心、达拉斯的得克萨斯苏格兰仪式医院和西北大学都有预约。这些有才华的人已经从不同的程序与皮肤病学,风湿病学,神经病学,儿科和人类免疫学的亚专业招募。他们为临床试验提供了一套独特的资源,并在融合基础和临床科学方面有着良好的记录。事实上,该团队致力于将创新治疗从实验室工作台带到患者的床边。有了这样优秀的合作球员,系统生物学方法在这里提出了调查儿童和成人自身免疫性疾病。为此,提出了两项II期随机、双盲、安慰剂对照临床试验。第一项试验研究用阿那白滞素阻断IL-1是否会导致青少年皮肌炎患者的客观疾病改善。试验设计将证明:1)在研究早期接受阿那白滞素治疗的患者的改善时间是否早于接受后期治疗的患者; 2)在盲期第8周改善的患者比例是否在早期治疗组中显著更大。机制研究将利用基因表达谱分析来寻找一种新的JDM诊断测试以及疾病活动性测量和生物标志物,以跟踪和预测患者对治疗的反应。第二个临床项目提出在患有斑块状银肩病以及银肩病关节炎的患者中使用α-IL-17。具体地,该研究将评估a-IL-17在这些患者中的安全性和功效,并确定达到PASI 75或ACR 20的终点的时间和在24周时这种应答的可持续性。相关研究将建立血液转录标记物以预测用α-IL-17治疗的患者的临床应答,确定转录评分是否可用于评估疾病活性,并分析IL-17阻断对B和T细胞亚群的影响。 一个充满活力的临床研究人员团队聚集在BUR,对自身免疫性疾病进行最先进的临床试验,将具有巨大的价值,并加速将研究从实验室工作台带到床边的过程。该研究小组提出了两项重要的试验,将评估α-IL-1治疗青少年皮肌炎和IL-17阻断银屑病疾病。
英文摘要
DESCRIPTION (provided by applicant): We propose to create an Autoimmunity Center of Excellence that will incorporate the efforts of clinicians, human immunologists (both basic and translational), physician-scientists with clinical expertise and research experience in autoimmunity, bioinformaticians, and geriomics/systems biologists. Together, the assembled group has an extensive background in clinical trials and a proven track record for merging basic and clinical science. This team is committed to bringing innovative treatments from the laboratory bench to their patients' bedside. Within this collaborative setting, a systems biology approach is proposed to focus on both pediatric and adult autoimmune diseases. The goals of the Center are: 1) To assess the efficacy of novel targeted therapies, 2) To develop simple and robust biomarkers using state-of-the-art genomic approaches, 3) To understand the role of recently identified T cell subsets in disease pathogenesis, and 4) To assess antigen-specific responses in pediatric and adult autoimmune diseases. These projects will provide a better understanding of the pathogenesis of specific autoimmune diseases and allow us to develop a strategy to assess disease activity based on novel transcriptional markers as well as to identify autoantigen-specific immune responses. The Center will deliver: 1) Innovative clinical trials targeting specific cytokines in psoriasis & dermatomyositis. 2) Development of biomarkers for dermatomyositis, psoriasis, lupus and multiple sclerosis. 3) Identification of novel therapeutic targets in dermatomyositis. 4) Development of assays to test autoantigen-specific immune responses. 5) Development of a unique microarray database of human autoimmune diseases. CLINICAL COMPONENT (Cush, J) CLINICAL COMPONENT DESCRIPTION (provided by applicant): Baylor Institute for Immunology Research aims to bring together a distinguished team of clinical investigators to conduct cutting-edge clinical trials on specific autoimmune diseases. This unique group of investigators and clinicians has appointments at Baylor University Medical Center, UT Southwestern Medical Center, Texas Scottish Rite Hospital in Dallas and Northwestern University. These talented individuals have been enlisted from diverse programs with subspecialties in dermatology, rheumatology, neurology, pediatrics, and human immunology. They provide a set of inimitable resources for clinical trials and have a proven track record for merging basic and clinical science. Indeed, this team is committed to bringing innovative treatments from the laboratory bench to their patients' bedside. With such outstanding collaborative players, a systems biology approach is proposed here which investigates both pediatric and adult autoimmune disease. To this end, two Phase II randomized, double-blind, placebo-phase controlled clinical trials are proposed. The first trial investigates whether blocking IL-1 with Anakinra will result in objective disease improvement for patients with Juvenile Dermatomysitis. The trial design will demonstrate: 1) if the time to improvement for patients receiving Anakinra early in the study will be earlier than those who receive later treatment; and 2) if the proportion of patients improved at week 8 of the blinded phase will be significantly greater in the early treatment group. Mechanistic studies will utilize gene expression profiling assays to find a novel diagnostic test for JDM as well as disease activity measures and biomarkers to follow and predict patients' response to therapy. The second clinical project proposes to use a-IL-17 in patients with plaque psoriasis as well as psoriatic arthritis. Specifically, this study will assess the safety and efficacy of a-IL-17 in these patients and determine both the time to achieve endpoints of a PASI 75 or ACR20 and sustainability of such responses at 24 weeks. Associated studies will establish blood transcriptional markers to predict clinical responses in patients treated with a-IL-17, determine if transcriptional scores can be used to assess disease activity, and analyze the effect(s) of IL-17 blockade on B and T cell subsets. A dynamic team of clinical investigators assembled at BUR to conduct state-of-the-art clinical trials on autoimmune disease would be of great value and accelerate the process of bringing research from the laboratory bench to the bedside. This team proposes two important trials that will assess a-IL-1 treatment in Juvenile Dermatomyositis and IL-17 blockade in psoriatic diseases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Project 2
Project 2
Early life respiratory viral infections shape immune development trajectories
Early life respiratory viral infections shape immune development trajectories
海外基金